NTRK1 and neoplasm: Recommended systemic treatments for patients with ATC are primarily taxanes, doxorubicin and platinum-based therapies for BRAF WT tumours, the dabrafenib/trametinib couplet for tumours with the BRAF V600E variant, and selective ALK, RET, or TRK inhibitors if an actionable fusion protein is identified (27, 28, 29).